Biotron expands HCV trial
Thursday, 14 August, 2008
Biotron [ASX: BIT] has expanded its Phase Ib/IIa clinical trial of its BIT225 hepatitis C treatment in an effort to maximise recruitment rates.
Testing will now be conducted at a Brisbane site in addition to the planned trial at a site in NSW.
The trial will be a placebo-controlled, randomised and multi-dose study examining the safety, pharmacokinetics and antiviral activity of the treatment.
The trial should be completed by the end of the year.
BIT225 targets the p7 protein of HCV, and has shown promising results in surrogate models of HCV infection.
TGA acts on melatonin imports with infringement notices totalling $99K
Laboratory testing of several imported unregistered melatonin products has confirmed them to be...
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
Australia's first cases of H5 avian influenza confirmed
Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...
